Heterocyclic compounds as alpha5-GABAA receptor modulators and uses thereof
By developing heterocyclic compounds with selective inhibitory activity on α5-GABAA receptor, the nonspecific binding problem of α5-GABAA receptor modulator in the prior art to hippocampal tissue is solved, and Alzheimer's disease is achieved Effective treatment of diseases such as
Patent Information
- Application Number
- CN202410720219.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-05-24
- Filing Date
- 2024-06-05
- Publication Date
- 2024-12-06
AI Technical Summary
Nonspecific binding of existing α5-GABAA receptor modulators to hippocampal tissue in the brain leads to adverse reactions and is difficult to effectively treat diseases related to learning and memory, such as Alzheimer's disease.
A new class of heterocyclic compounds developed that have selective inhibitory activity against the alpha5-GABAA receptors for the preparation of drugs used to treat, prevent or ameliorate diseases associated with the alpha5-GABAA receptor, including Alzheim Mercer's disease, polyinfarction dementia and pain.
The compounds have a significant regulatory effect on the α5-GABAA receptor, exhibit excellent pharmacokinetic properties, high safety and drug properties, and can effectively treat diseases mediated by the α5-GABAA receptor.
Smart Images

Figure CN119080754A_ABST
Abstract
Description
[0001] The present invention claims:
[0002] Priority to the prior application, patent application number 202310662536.9, entitled “Heterocyclic compounds as α5-GABAA receptor modulators and their uses”, filed with the State Intellectual Property Office of China on June 5, 2023;
[0003] The patent application number is 202410658952.6 and the name is "Application for α5-GABA A The priority of the prior application for "heterocyclic compounds as receptor modulators and their uses";
[0004] The entirety of said prior application is incorporated herein by reference. Technical Field
[0005] The present invention belongs to the field of medicine, and in particular, the present invention relates to α5-GABA A Heterocyclic compounds as receptor modulators and their uses. Background Art
[0006] GABA A GABA receptors are associated with a variety of diseases and are possible therapeutic targets, which has also promoted the A Research on the physiological and pharmacological effects of different receptor subunits. For example, studies using genetically modified mice have shown that the most widely distributed α5 subunit of the γ-aminobutyric acid A receptor (α5-GABA A Benzodiazepine receptors α2-GABA is the main target of benzodiazepines (BDZ) drugs for sedation and amnesia. A Receptors and α3-GABA A The receptors are associated with the anticonvulsant and antianxiety effects of drugs. A The receptor is an inhibitory receptor in the central nervous system of mammals, mainly distributed in the hippocampus of the brain. It has an inhibitory effect on hippocampal neurons by regulating the outward current of chloride ions. Its expression level in the cerebral cortex is very low and is almost not expressed in other brain regions. The hippocampus is the main site for cognitive functions such as learning and memory, which indicates that α5-GABA A Receptors may be related to cognitive functions such as learning and memory. In addition to BDZ drugs, there are many other drugs such as propofol, etomidate, barbiturates and neurosteroids that can stimulate GABA AThe allosteric regulatory sites of the receptors enhance the neural function of GABA, thereby producing corresponding pharmacological effects, which play an anesthetic, antianxiety, sedative or anti-epileptic role in clinical practice. A The non-specific binding of multiple subunits of the receptor leads to many adverse reactions such as drug tolerance, sedation, anxiety or convulsions. Therefore, researchers have been committed to studying and discovering the specific binding of a GABA receptor. A Drugs that have selective and specific effects on receptor subunits.
[0007] Numerous studies have shown that α5-GABA A Changes in receptor excitability can affect cognitive functions such as learning and memory, leading to the occurrence of some diseases such as postoperative cognitive dysfunction, pain, depression, schizophrenia and Down syndrome, etc. Allosteric modulators can treat or improve these diseases.
[0008] Considering α5-GABA A Many pharmaceutical companies, including Roche, are engaged in the study of the specific distribution and function of α5-GABA receptors in the hippocampus of the brain. A A large number of compounds have been synthesized in the study of receptor ligands, especially those targeting α5-GABA in the hippocampus of the brain. A α5-GABA receptor inverse agonists, of which α5IA and MRK-016 have shown good effects in treating cognitive diseases in animal disease models and human trials, especially in treating Alzheimer's disease. A Receptor inverse agonists can be used to treat cognitive diseases, especially Alzheimer's disease. Patent application US20110224278A1 discloses a novel α5-GABA A Inverse agonists of the receptors may be used to treat multi-infarct dementia and stroke-related disorders. Summary of the invention
[0009] The purpose of the present invention is to provide a new class of compounds, which have α5-GABA A The modulatory activity of receptors, in particular, with α5-GABA A To this end, the present invention also provides these compounds and pharmaceutically acceptable salts thereof for use in the preparation and manufacture of drugs for treating, preventing, or improving diseases related to α5-GABA A The invention also provides a method for preparing the compound of formula I, and an intermediate useful in such method.
[0010] In the first aspect of the present invention, there is provided a compound of formula I, a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof:
[0011]
[0012] in,
[0013] X 1 N or C;
[0014] X 2 N, O, S or CR 5 ;
[0015] Dashed lines represent single or double bonds;
[0016] m is selected from 0, 1, 2, 3, 4 or 5;
[0017] Ring A does not exist or is selected from a benzene ring, a 5-6 membered heteroaromatic ring; wherein,
[0018] When ring A does not exist, m is 1 and R 1 With X 1 connected;
[0019] R 1 Selected from hydrogen, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 3-7 Cycloalkyl or 3-6 membered heterocycloalkyl; 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 3-7 The cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted by 1-4 substituents selected from the group consisting of deuterium, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl;
[0020] R 2 Selected from hydrogen, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, 3-7 membered heterocycloalkyl or 5-6 membered heteroaryl; the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, 3-7 membered heterocycloalkyl or 5-6 membered heteroaryl are optionally substituted with 1-4 substituents selected from the group consisting of deuterium, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C3-7 Cycloalkyl;
[0021] L is selected from -CH 2 -O-, -CH(R 6 )-O- or -C(=O)-NR a -;
[0022] Ring B is selected from 5-14 membered heteroaromatic rings;
[0023] n is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8;
[0024] Ring D is absent or selected from 4-6 membered heterocycloalkyl, 3-6 membered cycloalkyl;
[0025] p is 0, 1, 2, 3, 4, 5, 6 or 7;
[0026] R 3 and R 4 are each independently selected from hydrogen, halogen, hydroxy, amino, cyano, oxo, -C 0-6 Alkyl-C(=O)R a -C 0-6 Alkyl, -C 0-6 Alkyl-C(=O)OR a -C 0-6 Alkyl, -C 0-6 Alkyl-C(=O)NR a R b -C 0-6 Alkyl, -C 0-6 Alkyl-NR a R b -C 0-6 Alkyl, -C 0-6 Alkyl-NR a C(=O)R b -C 0-6 Alkyl, -C 0-6 Alkyl-NR a SO 2 R b -C 0-6 Alkyl, -C 0-6 Alkyl-SO 2 R a -C 0-6 Alkyl, -C 0-6 Alkyl-SO 2 NR a R b -C 0-6 Alkyl, C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl, 6-10 membered heteroaryl; the C 1-6 Alkyl, C 3-7Cycloalkyl, 3-6 membered heterocycloalkyl, 6-10 membered heteroaryl are optionally substituted by 1-4 substituents selected from the following groups: deuterium, halogen, oxo, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;
[0027] M is absent or selected from O;
[0028] R 5 Selected from hydrogen, deuterium, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl; said C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 The cycloalkyl group is optionally substituted by 1 to 4 substituents selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;
[0029] R 6 Selected from deuterium, halogen, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl; said C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 The cycloalkyl group is optionally substituted by 1 to 4 substituents selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;
[0030] R a and R b are each independently selected from hydrogen, deuterium, halogen, hydroxyl, amino, -C 0-6 Alkyl-S(=O) 2 -C 0-6 Alkyl, -C 0-6 Alkyl-P(=O) 2 -C 0-6 Alkyl, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH 2 、-NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 and the 3-6 membered heterocycloalkyl is a monocyclic ring containing 0, 1, 2 or 3 N atoms and 0, 1 or 2 atoms selected from O and S atoms.
[0031] In a preferred embodiment of the present invention, the R 3 and R 4 are each independently selected from hydrogen, halogen, hydroxy, amino, cyano, oxo, -C 0-6 Alkyl-C(=O)R a , -C 0-6 Alkyl-C(=O)OR a , -C 0-6 Alkyl-C(=O)NR a R b , -C 0-6 Alkyl-NR a R b , -C 0-6 Alkyl-NR a C(=O)R b , -C 0-6 Alkyl-NR a SO 2 R b , -C 0-6 Alkyl-SO 2 R a , -C 0-6 Alkyl-SO 2 NR a R b , C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl, 6-10 membered heteroaryl; the C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl, 6-10 membered heteroaryl are optionally substituted by 1-4 substituents selected from the following groups: deuterium, halogen, oxo, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl.
[0032] In a preferred embodiment of the present invention, Selected from
[0033] Preferably, the Selected from
[0034] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0035] Among them, ring A, ring B, ring D, R 1 , R 2 , R 3 , R 4, L, M, p, m and n are defined as described in the first aspect of the present invention.
[0036] In a preferred embodiment of the present invention, the ring A is absent or selected from a benzene ring or a 6-membered heteroaromatic ring; the 6-membered heteroaromatic ring contains 1, 2, or 3 heteroatoms;
[0037] m is 0, 1, 2, 3, 4 or 5;
[0038] R 1 Selected from hydrogen, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-7 Cycloalkyl, C 3-7 Halogenated cycloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy;
[0039] The heteroatom is selected from N, O, and S. When there are multiple heteroatoms, the heteroatoms are the same or different.
[0040] In a preferred embodiment of the present invention, the ring A is absent or is selected from a benzene ring, pyridine, pyrimidine, pyridazine, pyrazine or triazine.
[0041] In a preferred embodiment of the present invention, the ring A is absent or selected from a benzene ring or pyridine.
[0042] In a preferred embodiment of the present invention, the ring A is selected from *End and X 1 connect.
[0043] In a preferred embodiment of the present invention, Selected from For example
[0044] In a preferred embodiment of the present invention, when ring A is absent, m is 1, R 1 With X 1 connected.
[0045] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0046]
[0047] Among them, ring B, ring D, R 1 , R 2 , R 3 , R 4 , L, M, m, n and p are defined as described in the first aspect of the present invention.
[0048] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0049]
[0050] Among them, ring B, ring D, R 1 , R 2 , R 3 , R 4 , L, M, n and p are defined as described in the first aspect of the present invention.
[0051] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0052]
[0053] Among them, ring A, ring B, ring D, R 1 , R 2 , R 3 , R 4 , M, m, n and p are defined as described in the first aspect of the present invention.
[0054] In a preferred embodiment of the present invention, the compound is selected from the following structures:
[0055]
[0056] Among them, ring B, R 1 , R 2 , R 3 , m and n are as defined in the first aspect of the present invention;
[0057] When M does not exist, rings D and R 4 and p do not exist at the same time;
[0058] When M is selected from O, ring D, R 4 and p are as defined in the first aspect of the present invention. In a preferred embodiment of the present invention, the ring B is selected from a 5-14 membered heteroaromatic ring containing 1, 2, 3, 4 or 5 heteroatoms;
[0059] Preferably, the heteroatom is selected from N, O, and S; when there are multiple heteroatoms, the heteroatoms are the same or different;
[0060] Preferably, ring B is selected from acridinyl, carbazolyl, cinnolinyl, quinoxalinyl, quinazolinyl, pyrazolyl, indolyl, isoindolyl, benzotriazolyl, furanyl, thienyl, pyridomorpholinyl, pyridopiperidinyl, pyridopyrrolidyl, benzothienyl, benzofuranyl, benzodioxane, benzodioxabenzophenone, quinolinyl, isoquinolinyl, oxazolyl, isoxazolyl, benzoxazolyl, tetrahydronaphthyridine, imidazolyl, pyrazinyl , pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrahydroquinolinyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, triazinyl, tetrazinyl, tetrazolyl, xanthenyl, phenazinyl, phenothiazinyl, phenoxazinyl, aza-zepinyl, oxa-zepinyl, thia-zepinyl, hexahydropyrazinopyrido-oxazine, 6,7,8,9-tetrahydropyrido[2',3':4,5]imidazo[1,2-a]pyrazine, and the like;
[0061] More preferably, ring B is selected from pyridine, pyrimidine, pyridazine, tetrahydronaphthyridine, pyridopiperidine,
[0062] In a preferred embodiment of the present invention, the ring B is selected from pyridine, pyrimidine, pyridazine, tetrahydronaphthyridine, pyridopiperidine,
[0063]
[0064] In a preferred embodiment of the present invention, the ring B is selected from * terminal is connected to L.
[0065] In a preferred embodiment of the present invention, Selected from * terminal is connected to L.
[0066] In a preferred embodiment of the present invention, the L is selected from -CH 2 -O-, -CH(R 6 )-O- or -C(=O)-NR a R b -;
[0067] The R 6 Selected from C 1-3 Alkyl or C 3-5 Cycloalkyl; said C 1-3 Alkyl or C 3-5 The cycloalkyl group is optionally substituted by 1 to 4 substituents selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;
[0068] Preferably, L is selected from -CH 2 -O-, -CH(CH3 )-O- or -C(=O)-NH 2 -.
[0069] In a preferred embodiment of the present invention, the L is selected from -CH 2 -O-, -CH(CH 3 )-O- or -C(=O)-NH 2 -.
[0070] In a preferred embodiment of the present invention, the L is selected from -CH 2 -O-, -CH(R 6 )-O- or -C(=O)-NR a -;
[0071] The R 6 Selected from C 1-3 Alkyl or C 3-5 Cycloalkyl; said C 1-3 Alkyl or C 3-5 The cycloalkyl group is optionally substituted by 1 to 4 substituents selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl.
[0072] In a preferred embodiment of the present invention, the L is selected from -CH 2 -O-, -CH(CH 3 )-O- or -C(=O)-NH-.
[0073] In a preferred embodiment of the present invention, said L is selected from (like ), *End and connect.
[0074] In a preferred embodiment of the present invention, the ring D is absent or selected from 4-6 membered heterocycloalkyl and 3-6 membered cycloalkyl containing 1-3 heteroatoms;
[0075] Preferably, the heteroatom is selected from N, O, and S; when there are multiple heteroatoms, the heteroatoms are the same or different.
[0076] In a preferred embodiment of the present invention, the ring D is absent or is selected from cyclopropyl, cyclobutyl, cyclopentyl, azetidine, pyrrolidine, piperidine, and piperazine.
[0077] In a preferred embodiment of the present invention, the ring D is selected from
[0078] In a preferred embodiment of the present invention, Selected from
[0079] In a preferred embodiment of the present invention, the R 1 Selected from hydrogen, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl, C 1-6 Alkoxy; the C 1-6 Alkyl, C 3-7 Cycloalkyl, C 1-6 The alkoxy group is optionally substituted with 1 to 4 substituents selected from the group consisting of deuterium, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;
[0080] m is selected from 0, 1, 2, 3, 4 or 5;
[0081] Preferably, R 1 Selected from F, methyl, cyclopropyl, methoxy, trifluoromethyl, difluoromethyl, monofluoromethyl.
[0082] In a preferred embodiment of the present invention, the R 1 Selected from halogen, C 1-6 Alkyl, C 3-7 Cycloalkyl, C 1-6 Alkoxy, haloalkyl.
[0083] In a preferred embodiment of the present invention, the R 1 Selected from F, methyl, cyclopropyl, methoxy, trifluoromethyl, difluoromethyl, monofluoromethyl.
[0084] In a preferred embodiment of the present invention, the R 2 Selected from halogen, C 1-6 Alkyl, C 3-7 Cycloalkyl, C 1-6 Alkoxy; the C 1-6 Alkyl, C 3-7 Cycloalkyl, C 1-6 The alkoxy group is optionally substituted with 1 to 4 substituents selected from the group consisting of deuterium, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;
[0085] Preferably, R 2 Selected from methyl.
[0086] In a preferred embodiment of the present invention, the R 3 is selected from hydrogen, halogen, hydroxy, amino, cyano, oxo, -C 0-6 Alkyl-C(=O)R a -C 0-6Alkyl, -C 0-6 Alkyl-C(=O)OR a -C 0-6 Alkyl, -C 0-6 Alkyl-C(=O)NR a R b -C 0-6 Alkyl, C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl; the C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl are optionally substituted by 1-4 substituents selected from the following groups: deuterium, halogen, oxo, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;
[0087] n is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8;
[0088] Preferably, R 3 is selected from hydrogen, halogen, oxo, -C(=O)R a 、-C(=O)NR a R b -C 0-3 Alkyl, C 1-3 Alkyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidine, piperidine, piperazine, piperidone, piperazinone.
[0089] In a preferred embodiment of the present invention, the R 3 is selected from hydrogen, halogen, hydroxy, amino, cyano, oxo, -C 0-6 Alkyl-C(=O)R a , -C 0-6 Alkyl-C(=O)OR a , -C 0-6 Alkyl-C(=O)NR a R b , C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl; the C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl are optionally substituted by 1-4 substituents selected from the following groups: deuterium, halogen, oxo, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl.
[0090] In a preferred embodiment of the present invention, the R 3 is selected from hydrogen, halogen, oxo, -C(=O)R a 、-C(=O)NR a Rb , C 1-3 Alkyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidine, piperidine, piperazine, piperidone, piperazinone.
[0091] In a preferred embodiment of the present invention, the R 3 Selected from hydrogen, oxo, -C(=O)-CH 3 、-C(=O)NH 2 -C 0-3 Alkyl, methyl, piperazinone; n is selected from 0 or 1.
[0092] In a preferred embodiment of the present invention, the R 3 Selected from hydrogen, oxo, -C(=O)-CH 3 、-C(=O)NH 2 、-C(=O)NH-C 1-3 Alkyl, methyl, piperazinone; n is selected from 0 or 1.
[0093] In a preferred embodiment of the present invention, the R 3 Selected from hydrogen, oxo, -C(=O)-CH 3 、-C(=O)NH 2 、-C(=O)NH-C 1-3 Alkyl, methyl, piperazinone, methyl substituted piperazinone.
[0094] In a preferred embodiment of the present invention, the R 3 Selected from hydrogen, oxo, -C(=O)-CH 3 、-C(=O)NH 2 , methyl,
[0095] In a preferred embodiment of the present invention, n is selected from 0 or 1.
[0096] In a preferred embodiment of the present invention, the R 4 is selected from hydrogen, halogen, hydroxy, amino, cyano, oxo, -C 0-6 Alkyl-C(=O)R a -C 0-6 Alkyl, -C 0-6 Alkyl-C(=O)OR a -C 0-6 Alkyl, -C 0-6 Alkyl-C(=O)NR a R b -C 0-6 Alkyl, C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl; the C 1-6Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl are optionally substituted by 1-4 substituents selected from the following groups: deuterium, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;
[0097] p is 0, 1, 2, 3, 4, 5, 6 or 7;
[0098] Preferably, R 4 Selected from hydrogen, oxo, -C(=O)-CH 3 、-C(=O)NH 2 -C 0-3 Alkyl, methyl;
[0099] p is selected from 0, 1 or 2.
[0100] In a preferred embodiment of the present invention, the R 4 is selected from hydrogen, halogen, hydroxy, amino, cyano, oxo, -C 0-6 Alkyl-C(=O)R a , -C 0-6 Alkyl-C(=O)OR a , -C 0-6 Alkyl-C(=O)NR a R b , C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl; the C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl are optionally substituted by 1-4 substituents selected from the following groups: deuterium, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;
[0101] In a preferred embodiment of the present invention, the R 4 Selected from hydrogen, oxo, -C(=O)-CH 3 、-C(=O)NH 2 、-C(=O)NH-C 1-3 Alkyl, methyl; p is selected from 0, 1 or 2.
[0102] In a preferred embodiment of the present invention, the R 4 Selected from hydrogen, oxo, -C(=O)-CH 3 、-C(=O)NH 2 ,methyl.
[0103] In a preferred embodiment of the present invention, said p is selected from 0, 1 or 2.
[0104] In a preferred embodiment of the present invention, the compound comprises:
[0105]
[0106] The second aspect of the present invention is a pharmaceutical composition, comprising the compound of formula I as described in the first aspect, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug; and a pharmaceutically acceptable carrier.
[0107] In a third aspect of the present invention, the use of the compound of formula I as described in the first aspect, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, or the use of the pharmaceutical composition as described in the second aspect, the use includes:
[0108] Regulation of α5-GABA A Receptors;
[0109] and / or, prevention and / or treatment of α5-GABA A Receptor-related diseases;
[0110] And / or, preparing a method for regulating α5-GABA A Receptor, and / or prevention and / or treatment of α5-GABA A A drug, pharmaceutical composition or preparation for a receptor-related disease.
[0111] Provided is a compound of formula I as described in the first aspect, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, or the pharmaceutical composition as described in the second aspect, which is expected to be used for pain, Alzheimer's disease, multi-infarct dementia or stroke.
[0112] Pain that should be mentioned is neuropathic pain, inflammatory pain or cancer pain.
[0113] The pain that should be mentioned is selected from the group consisting of headache, facial pain, neck pain, shoulder pain, back pain, chest pain, abdominal pain, low back pain, lower limb pain, musculoskeletal pain, vascular pain, gout, arthritis pain, visceral pain, pain caused by infectious diseases, polyostotic pain, sickle cell anemia, autoimmune diseases, pain associated with multiple sclerosis or inflammation, chronic pain caused by injury or surgery, nociceptive pain, painful diabetes, trigeminal neuralgia, lumbar or cervical radiculopathy, glossopharyngeal neuralgia, autonomic reflex pain, reflex sympathetic dystrophy, nerve root avulsion, cancer, chemical injury, toxins, nutritional deficiencies, viral or bacterial infections, pain associated with degenerative osteoarthritis.
[0114] Infectious diseases that should be mentioned are selected from AIDS or postherpetic neuralgia.
[0115] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention.
[0116] Beneficial Effects
[0117] The present inventors have unexpectedly developed a compound or a pharmaceutically acceptable salt thereof, a preparation method and use thereof through extensive and in-depth research.
[0118] The present invention provides a compound of formula I, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, wherein the compound of formula I has an effect on α5-GABA A The receptor has a significant regulatory effect and can treat diseases caused by α5-GABA A Receptor-mediated diseases or conditions, showing excellent pharmacokinetic properties, with high safety and drugability.
[0119] The present invention provides a method for preparing the compound shown in I, its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs and intermediates. The method is simple to operate, high in yield and purity, and can be used for industrial production of medicines.
[0120] Definition and explanation of terms
[0121] Unless otherwise specified, the definitions of groups and terms recorded in the specification and claims of this application, including their definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, definitions of specific compounds in examples, etc., can be arbitrarily combined and combined with each other. The group definitions and compound structures after such combination and combination shall fall within the scope recorded in the specification of this application.
[0122] Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by those skilled in the art to which the subject matter of the claims pertains. Unless otherwise indicated, all patents, patent applications, and publications cited herein are incorporated herein by reference in their entirety. If there are multiple definitions of a term herein, the definition in this chapter shall prevail.
[0123] It should be understood that the above brief description and the detailed description below are exemplary and are only used for explanation, and do not impose any restrictions on the subject matter of the present invention. In this application, unless otherwise specifically stated, the use of the singular also includes the plural. It must be noted that unless otherwise clearly stated in the text, the singular form used in this specification and claims includes the plural form of the referred thing. It should also be noted that unless otherwise stated, the "or" and "or" used mean "and / or". In addition, the term "including" and other forms, such as "including", "containing" and "containing" are not restrictive.
[0124] Definitions of standard chemical terms can be found in references (including Carey and Sundberg "ADVANCED ORGANIC CHEMISTRY 4 THE ED." Vols. A (2000) and B (2001), Plenum Press, New York). Unless otherwise stated, conventional methods within the technical scope of the art, such as mass spectrometry, NMR, IR and UV / VIS spectroscopy and pharmacological methods, are used. Unless specifically defined, the terms used herein in the relevant descriptions of analytical chemistry, organic synthetic chemistry, and drugs and medicinal chemistry are known in the art. Standard techniques can be used in chemical synthesis, chemical analysis, drug preparation, formulation and delivery, and in the treatment of patients. For example, the manufacturer's instructions for use of the kit can be used, or the reaction and purification can be carried out in a manner known in the art or in accordance with the description of the present invention. The above-mentioned techniques and methods can usually be implemented according to the descriptions in the multiple summaries and more specific documents cited and discussed in this specification, according to conventional methods well known in the art. In this specification, groups and substituents thereof can be selected by those skilled in the art to provide stable structural parts and compounds.
[0125] When substituents are described by conventional chemical formulas written from left to right, the substituents also include chemically equivalent substituents that would result if the formula were written from right to left. 2 O is equivalent to OCH 2 As used herein, As used herein, "R 1 ”, “R1” and “R 1 " have the same meaning and can be used interchangeably. 2 Other symbols and similar definitions have the same meaning.
[0126] The section headings used herein are only for the purpose of organizing the article and should not be interpreted as limitations on the subject matter described. All documents or portions of documents cited in this application, including but not limited to patents, patent applications, articles, books, operating manuals and papers, are incorporated herein by reference in their entirety.
[0127] In addition to the foregoing, when used in the specification and claims of the present application, the following terms have the meanings indicated below unless otherwise specifically stated.
[0128] When the numerical range described in the specification and claims of this application is understood as an "integer", it should be understood that the two endpoints of the range and each integer in the range are recorded. For example, "an integer from 0 to 14" should be understood as recording each integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14.
[0129] In the present application, when indicating the number of substituents, the term "one or more" refers to one substitution to the maximum possible number of substitutions, i.e., replacing one hydrogen to all hydrogens are replaced by substituents. When indicating the number of substituents, the term "1-4" refers to 1, 2, 3 or 4 substitutions, i.e., 1, 2, 3 or 4 hydrogens are replaced by substituents.
[0130] In the present application, "saturated, partially saturated or unsaturated" includes substituents saturated with hydrogen, substituents completely unsaturated with hydrogen and substituents partially saturated with hydrogen.
[0131] As used herein, the term "halogen" by itself or as part of another substituent refers to fluorine, chlorine, bromine, iodine.
[0132] As used herein, the term "hydroxy" by itself or as part of another substituent refers to -OH.
[0133] As used herein, the term "cyano" by itself or as part of another substituent refers to -CN.
[0134] As used herein, the term "amino" when used alone or as part of another substituent group refers to -NH 2 .
[0135] In this application, the term "alkyl" when used alone or as part of other substituents means a straight or branched hydrocarbon chain radical consisting only of carbon atoms and hydrogen atoms, having, for example, 1 to 6 carbon atoms and connected to the rest of the molecule by a single bond. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl and hexyl. Alkyl groups may be unsubstituted or substituted with one or more suitable substituents. Alkyl groups may also be isotopic isomers of natural abundance alkyl groups that are rich in isotopes of carbon and / or hydrogen (i.e., deuterium or tritium). .
[0136] In this application, the term "C α-β "Alkyl" refers to an alkyl group containing a minimum of α and a maximum of β carbon atoms in a branched or linear relationship or any combination of the three, where α and β represent integers, and can also be represented by "C α- C βThe alkyl groups described in this section may also contain one or two double bonds or triple bonds. 0 The designation of alkyl indicates a direct bond. 1-6 Examples of alkyl groups include, but are not limited to, the following:
[0137] In this application, "benzo group", alone or in combination, refers to a divalent group C 4 H 4 =, one of which is -CH=CH-CH=CH-, which forms a benzene-like ring when attached to another ring at the ortho position, such as tetralin, indole, etc.
[0138] In this application, the term "C α-β "Haloalkyl" refers to an alkyl group as described above wherein any number (at least one) of the hydrogen atoms attached to the alkyl chain are replaced by fluorine, chlorine, bromine or iodine.
[0139] As used herein, the term "alkoxy" by itself or as part of another substituent refers to the group -OR Q , where R Q is "alkyl" as defined above.
[0140] In the present application, the term "oxo" alone or as part of other substituents refers to the replacement of two hydrogen atoms on a methylene group by oxygen, that is, the methylene group is replaced by a carbonyl group, representing =0.
[0141] As used herein, the term "thio" by itself or as part of another substituent refers to the replacement of two hydrogen atoms on a methylene group with sulfur, representing =S.
[0142] As used herein, the term "cycloalkyl" or "carbocyclyl" when used alone or as part of another substituent refers to a cyclic alkyl group. m -C n Cycloalkyl" or "C m-n "Cycloalkyl" is understood to mean a saturated, unsaturated or partially saturated carbon ring having m to n atoms. For example, "3-15 membered cycloalkyl" or "C 3 -C 15"Cycloalkyl" refers to a cyclic alkyl group containing 3 to 15, 3 to 9, 3 to 7, 3 to 6 or 3 to 5 carbon atoms, which may contain 1 to 4 rings. "5-8 membered cycloalkyl" contains 5-8 carbon atoms. It includes monocyclic, bicyclic, tricyclic, spirocyclic or bridged rings. Examples of unsubstituted cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and adamantyl, or a bicyclic hydrocarbon group such as a decalin ring. The cycloalkyl group may be substituted with one or more substituents. In some embodiments, the cycloalkyl group may be a cycloalkyl group fused to an aryl or heteroaryl group. The term "C 3 -C 6 "Cycloalkyl" is understood to mean a saturated monovalent monocyclic or bicyclic hydrocarbon ring having 3 to 6 carbon atoms, including fused or bridged polycyclic ring systems. For example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
[0143] In the present application, the term "heterocycloalkyl" or "heterocyclyl" refers to a cycloalkyl group in which one or more (in some embodiments, 1 to 3) carbon atoms are replaced by heteroatoms, such as but not limited to N, O, S and P, when alone or as part of other substituents. "Heterocycloalkyl" or "heterocyclyl" can be saturated or unsaturated, but not aromatic. "Heterocycloalkyl" or "heterocyclyl" can also contain 1, 2 or 3 rings, including bridged rings and spirocyclic structures. The term "3-8 membered heterocyclyl" or "3-8 membered heterocycloalkyl" should be understood to mean a monocyclic, bicyclic or tricyclic ring having 3 to 8 atoms, wherein the heteroatoms are preferably selected from N, O and S. It should be understood that when the total number of S atoms and O atoms in the heterocyclyl exceeds 1, these heteroatoms are not adjacent to each other, such as 3-6 membered heterocycloalkyl or 3-7 membered heterocycloalkyl. Examples of heterocycloalkyl include, but are not limited to, tetrahydroisoquinolyl, tetrahydroquinolyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydrothiopyranyl.
[0144] In this application, the term "C α-β "Cycloalkenyl" refers to a monocyclic group having α to β atoms, a double bond, but no aromaticity. Examples of cycloalkenyl are cyclopropene, cyclobutene, cyclohexene, cyclobutadiene, cyclopentadiene, cycloheptatriene, cyclooctatetraene, etc.
[0145] In the present application, the term "heteroalkene ring" when used alone or as part of other substituents refers to a monocyclic group with heteroatoms (the monocyclic group has double bonds but is not aromatic), preferably a monocyclic ring containing 1, 2 or 3 ring heteroatoms independently selected from N, O and S. Examples of heterocycloalkenyl groups are: dihydrofuranyl, dihydrothienyl, dihydropyrrolyl, dioxolyl, dihydroimidazolyl, dihydropyrazolyl, dihydrothiazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrothiadiazolyl, dihydrotriazolyl, dihydrotetrazolyl, tetrahydropyridinyl, 3,4-dihydro-2H-pyran, pyranyl, thiopyranyl, dihydropyridinyl, dihydropyrazinyl, dihydropyrimidinyl, oxazinyl, dihydrotetrazolyl, etc. The term "heteroalkene ring" can be used interchangeably with the term "heterocycloalkenyl".
[0146] In the present application, the term "aryl" or "aromatic ring" refers to a monovalent aromatic carbocyclic ring system containing 6-14, preferably 6-10 carbon atoms and having at least one aromatic ring or multiple fused rings in which at least one ring is an aromatic ring, when used alone or as part of other substituents. Examples of aryl include, but are not limited to, phenyl, naphthyl, biphenyl or indanyl, etc.
[0147] In the present application, the term "5-14 membered heteroaromatic ring" or "5-14 membered heteroaryl" when alone or as part of other substituents means a stable monocyclic, bicyclic or tricyclic ring having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, wherein at least one ring is aromatic and at least one ring contains 1-5 heteroatoms independently selected from N, O and S. It should be understood that when the total number of S atoms and O atoms in the heteroaryl exceeds 1, these heteroatoms are not adjacent to each other. The 5-14 membered heteroaryl can be attached to the rest of the molecule through a heteroatom or a carbon atom. 5-14 membered heteroaryl groups within the scope of this definition include, but are not limited to, acridinyl, carbazolyl, cinnolinyl, quinoxalinyl, quinazolinyl, pyrazolyl, indolyl, isoindolyl, 1H,3H-1-oxoisoindolyl, benzotriazolyl, furanyl, thienyl, pyridomorpholinyl, pyridopiperidinyl, pyridopyrrolidinyl, benzothienyl, benzofuranyl, benzodioxane, benzodioxine, quinolinyl, isoquinolinyl, oxazolyl, isoxazolyl, benzotriazolyl, benzothiophene, benzofuranyl, benzodioxane, benzodioxine, quinolinyl, isoquinolinyl, oxazolyl, isoxazolyl, benzotri ... 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,4,5-tetrazinyl, tetrazolyl, xanthenyl, phenazinyl, phenothiazinyl, phenoxazinyl, aza-zepinyl, oxa-zepinyl and thia-zepinyl. The term "5-10 membered heteroaromatic ring" or "5-10 membered heteroaryl" is understood as a monocyclic, bicyclic or tricyclic ring having 5 to 10 atoms, wherein at least one ring is aromatic and contains at least 1 to 5 heteroatoms independently selected from N, O and S. Examples of 5-10 membered heteroaromatic rings include, but are not limited to, furanyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, diazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridomorpholinyl, pyridopiperidinyl, pyridopyrrolidinyl, and the like.
[0148] In the present application, the term "monocyclic" when alone or as part of other substituents means a group having only one ring, which may be saturated, unsaturated or partially saturated, and may be a carbocyclic ring (all ring atoms are carbon atoms) or a heterocyclic ring (in addition to carbon atoms, the ring atoms include, for example, 1, 2 or 3 heteroatoms, such as N, O or S).
[0149] In the present application, the term "bicyclic" means a group having two connected rings, either alone or as part of other substituents. Bicyclic rings can be carbocyclic rings (all ring atoms are carbon atoms) or heterocyclic rings (in addition to carbon atoms, the ring atoms include, for example, 1, 2 or 3 heteroatoms, such as N, O or S). Both rings can be aliphatic (e.g., decalin and norbornane), or can be aromatic (e.g., naphthalene), or a combination of aliphatic and aromatic (e.g., tetralin). Bicyclic rings include (a) spirocyclic compounds, in which the two rings share only one single atom (spiro atom, which is usually a quaternary carbon). Examples of spirocyclic compounds include, but are not limited to:
[0150]
[0151] It also includes spirocycloalkyl groups that share a spiro atom with a heterocycloalkyl group. Non-limiting examples include:
[0152]
[0153] (b) Fused bicyclic compounds, where the two rings share two adjacent atoms. In other words, the rings share one covalent bond, i.e., the bridgehead atoms are directly connected (e.g., α-thujene and decalin). Examples of fused bicyclic rings include, but are not limited to:
[0154]
[0155] and (c) bridged bicyclic compounds, wherein the two rings share three or more atoms and the two bridgehead atoms are separated by a bridge comprising at least one atom. For example, norbornane, also known as bicyclo[2.2.1]heptane, can be considered as a pair of cyclopentane rings, each ring sharing three of their five carbon atoms. Examples of bridged bicyclic rings include, but are not limited to:
[0156]
[0157] In this application, NR, alone or as part of another substituent, a R a The group can be or it may include two R a The groups together form a ring which optionally contains N, O or S atoms and may also include the following groups, for example:
[0158] In the present application, the group N(C α-β Alkyl)C α-β Alkyl groups (wherein α and β are as defined above) include groups wherein two C α-βThe alkyl groups together form a substituent of a ring (optionally containing N, O or S atoms) and include the following groups, for example:
[0159] In the present application, the term "inert solvent" includes, but is not limited to: toluene, benzene, water, methanol, ethanol, isopropanol, ethylene glycol, N-methylpyrrolidone, dimethyl sulfoxide, tetrahydrofuran, dichloromethane, chloroform, 1,2-dichloroethane, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dioxane, or a combination thereof.
[0160] Compounds provided herein include intermediates that can be used to prepare compounds provided herein, which contain reactive functional groups (such as but not limited to carboxyl, hydroxyl and amino moieties), and also include protected derivatives thereof. "Protected derivatives" are those compounds in which one or more reactive sites are blocked by one or more protecting groups (also referred to as protecting groups). Suitable carboxyl moiety protecting groups include benzyl, tert-butyl, etc., and isotopes, etc. Suitable amino and amido protecting groups include acetyl, trifluoroacetyl, tert-butyloxycarbonyl, benzyloxycarbonyl, etc. Suitable hydroxyl protecting groups include benzyl, etc. Other suitable protecting groups are well known to those of ordinary skill in the art.
[0161] In the present application, the term "optionally substituted by" or "optionally substituted by" means that the specified group is unsubstituted or substituted by one or more substituents independently selected from possible substituents. For example, "aryl is optionally substituted by 1-4 substituents independently selected from the following groups: halogen, cyano, hydroxyl, C 1-6 "Alkyl" means that the aryl group is unsubstituted or substituted by 1, 2, 3 or 4 substituents independently selected from the following groups: halogen, cyano, hydroxyl, C 1-6 The term "alkyl" refers to an alkyl group, and the description includes both substituted and unsubstituted aryl groups.
[0162] In the present application, the term "salt" or "pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts. The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms that are suitable for use in contact with human and animal tissues within the scope of sound medical judgment without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0163] In this application, the term "pharmaceutically acceptable acid addition salt" refers to a salt formed with an inorganic acid or organic acid that retains the biological effectiveness of the free base without other side effects. "Pharmaceutically acceptable base addition salt" refers to a salt formed with an inorganic base or organic base that retains the biological effectiveness of the free acid without other side effects. In addition to pharmaceutically acceptable salts, other salts are contemplated by the present invention. They can serve as intermediates in the purification of compounds or in the preparation of other pharmaceutically acceptable salts or can be used for the identification, characterization or purification of the compounds of the present invention.
[0164] In the present application, the term "amine salt" refers to the product obtained by neutralizing an alkyl primary amine, a secondary amine or a tertiary amine with an acid. The acid includes the inorganic acid or organic acid described in the present application.
[0165] In the present application, the term "stereoisomer" refers to isomers resulting from different spatial arrangements of atoms in molecules, including cis-trans isomers, enantiomers, diastereomers and conformational isomers.
[0166] Depending on the choice of starting materials and methods, the compounds of the invention may exist in the form of one of the possible isomers or a mixture thereof, for example as a pure optical isomer, or as a mixture of isomers, such as a racemic and diastereomeric mixture, depending on the number of asymmetric carbon atoms. When describing optically active compounds, the prefixes D and L or R and S are used to indicate the absolute configuration of the molecule with respect to the chiral center (or multiple chiral centers) in the molecule. The prefixes D and L or (+) and (–) are the symbols used to specify the rotation of plane polarized light caused by the compound, where (–) or L indicates that the compound is levorotatory. Compounds prefixed with (+) or D are dextrorotatory.
[0167] When the bonds to the chiral carbon in the formula of the present invention are depicted as straight lines, it should be understood that both the (R) and (S) configurations of the chiral carbon and the enantiomerically pure compounds and mixtures thereof produced therefrom are included within the scope of the general formula. The graphic representation of racemates or enantiomerically pure compounds herein is from Maehr, J. Chem. Ed. 1985, 62: 114-120. The absolute configuration of a stereocenter is indicated by a wedge-shaped bond and a dashed bond.
[0168] In the present application, the term "tautomer" refers to a functional group isomer resulting from the rapid movement of an atom in two positions in a molecule. The compounds of the present invention may exhibit tautomerism. Tautomeric compounds may exist in two or more interconvertible species. Prototropic tautomers arise from the migration of a covalently bonded hydrogen atom between two atoms. Tautomers generally exist in equilibrium, and attempts to separate a single tautomer generally produce a mixture whose physicochemical properties are consistent with a mixture of compounds. The position of equilibrium depends on the chemical properties within the molecule. For example, in many aliphatic aldehydes and ketones such as acetaldehyde, the keto form is predominant; whereas in phenols, the enol form is predominant. The present invention encompasses all tautomeric forms of the compounds.
[0169] In this application, "pharmaceutical composition" refers to a preparation of the compound of the present invention and a medium generally accepted in the art for delivering the biologically active compound to a mammal (e.g., a human). The medium includes a pharmaceutically acceptable carrier. The purpose of the pharmaceutical composition is to promote administration of the organism, facilitate the absorption of the active ingredient, and thus exert biological activity.
[0170] In this application, "pharmaceutically acceptable carrier" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the relevant governmental regulatory authorities as acceptable for human or livestock use.
[0171] In the present application, the term "solvate" means that the compound of the present invention or a salt thereof includes a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent forces between molecules. When the solvent is water, it is a hydrate.
[0172] In the present application, the term "prodrug" refers to a compound of the present invention that can be converted into a biologically active compound under physiological conditions or by solvolysis. The prodrug of the present invention is prepared by modifying the functional groups in the compound, and the modification can be removed by conventional operations or in vivo to obtain the parent compound. The prodrug includes a compound formed by connecting a hydroxyl or amino group in the compound of the present invention to any group. When the prodrug of the compound of the present invention is administered to a mammalian individual, the prodrug is cleaved to form a free hydroxyl group and a free amino group, respectively.
[0173] The compounds of the invention may contain unnatural proportions of atomic isotopes on one or more of the atoms that make up the compound. For example, the compounds may be labeled with radioactive isotopes, such as deuterium ( 2 H), tritium ( 3 H), iodine-125( 125 I) or C-14( 14C) All isotopic variations of the compounds of the present invention, whether radioactive or not, are included within the scope of the present invention.
[0174] In this application, the term "excipient" refers to a pharmaceutically acceptable inert ingredient. Examples of the type of the term "excipient" include, but are not limited to, binders, disintegrants, lubricants, glidants, stabilizers, fillers, and diluents. Excipients can enhance the handling characteristics of a pharmaceutical formulation, i.e., make the formulation more suitable for direct compression by increasing fluidity and / or adhesion.
[0175] As used herein, the term "treatment" and other similar synonyms include the following meanings:
[0176] (i) preventing a disease or condition from occurring in a mammal, particularly where such mammal is susceptible to the disease or condition but has not yet been diagnosed as having the disease or condition;
[0177] (ii) inhibiting a disease or condition, i.e. arresting its development;
[0178] (iii) alleviate the disease or condition, that is, cause regression of the disease or condition; or
[0179] (iv) alleviating the symptoms caused by the disease or condition.
[0180] The reaction temperature of each step can be appropriately selected according to the solvent, starting materials, reagents, etc., and the reaction time can also be appropriately selected according to the reaction temperature, solvent, starting materials, reagents, etc. After the reaction of each step is completed, the target compound can be separated and purified from the reaction system by common methods, such as filtration, extraction, recrystallization, washing, silica gel column chromatography, etc. In the case of not affecting the next step reaction, the target compound can also be directly used in the next step reaction without separation and purification. DETAILED DESCRIPTION
[0181] The technical solution of the present disclosure will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary illustrations and explanations of the present disclosure and should not be construed as limiting the scope of protection of the present disclosure. All technologies implemented based on the above content of the present disclosure are included in the scope of protection intended by the present disclosure.
[0182] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.
[0183] This application has the following definitions:
[0184] Symbol or unit:
[0185] IC 50 : Half inhibitory concentration, which refers to the concentration at which half of the maximum inhibitory effect is achieved
[0186] M: mol / L, for example, n-butyllithium (14.56 mL, 29.1 mmol, 2.5 M n-hexane solution) means a n-butyllithium n-hexane solution with a molar concentration of 2.5 mol / L
[0187] N: equivalent concentration, for example, 2N hydrochloric acid means 2 mol / L hydrochloric acid solution
[0188] RT: retention time
[0189] Reagents:
[0190] PE: Petroleum ether
[0191] EA: Ethyl acetate, also called EtOAc
[0192] DMF: N,N-dimethylformamide
[0193] DIPEA: N,N-diisopropylethylamine
[0194] RuPhos-Pd-G3: (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) methanesulfonate or (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate
[0195] Test method:
[0196] LCMS: Liquid chromatography-mass spectrometry
[0197] TLC: Thin layer chromatography
[0198] Example 1: Preparation of target compound I-1
[0199] 4-(6-(1-(1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)ethoxy)pyridazin-3-yl)piperazin-2-one
[0200]
[0201] The synthetic route of the target compound I-1 is as follows:
[0202]
[0203] Step 1: Synthesis of 1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazole-5-carboxylic acid
[0204]
[0205] Dissolve 1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazole-5-carboxylic acid ethyl ester (3.0 g, 10.67 mmol) in anhydrous tetrahydrofuran (20 mL) and methanol (5 mL), then weigh lithium hydroxide monohydrate (1.34 g, 32.0 mmol) and dissolve it in water (10 mL) and add it to the above solution. After the addition, the reaction solution was reacted at room temperature for 16 hours. TLC (PE:EA (V / V) = 3:1) showed that the reaction was complete. The reaction solution was extracted with ethyl acetate (20 mL × 3), the organic phases were combined, washed with water (15 mL × 2), the aqueous phases were combined, and the pH was adjusted to 3 with 2N hydrochloric acid, then extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with saturated brine (20 mL), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried to give 1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazole-5-carboxylic acid (2.80 g, crude product), which was used directly in the next step.
[0206] Step 2: Synthesis of 1-(4-(difluoromethyl)phenyl)-N-methoxy-N,4-dimethyl-1H-1,2,3-triazole-5-carboxamide
[0207]
[0208] Under ice bath conditions, 1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazole-5-carboxylic acid (2.80 g, 11.06 mmol) was dissolved in anhydrous acetonitrile (30 mL), then N,O-dimethylhydroxylamine hydrochloride (1.29 g, 13.27 mmol) and N,N-diisopropylethylamine (7.15 g, 55.29 mmol) were weighed, and then 1-propylphosphoric anhydride (11.95 g, 50% in EtOAc, 16.59 mmol) was slowly added dropwise under the same conditions. After the addition was complete, the reaction solution was reacted at room temperature for 16 hours. TLC (PE:EA=1:1) showed that the reaction was complete. Water (20 mL) was added to the reaction solution, and the reaction solution was extracted with ethyl acetate (30 mL×3). The organic phases were combined, washed with water (20 mL) and saturated brine (20 mL), respectively, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by normal phase silica gel column chromatography (PE / EtOAc (V / V) = 1:0-1:1) to give 1-(4-(difluoromethyl)phenyl)-N-methoxy-N,4-dimethyl-1H-1,2,3-triazole-5-carboxamide (2.70 g, yield: 82.41%).
[0209] Step 3: Synthesis of 1-(1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)ethan-1-one
[0210]
[0211] Under ice bath conditions and nitrogen protection, 1-(4-(difluoromethyl)phenyl)-N-methoxy-N,4-dimethyl-1H-1,2,3-triazole-5-carboxamide (1.40 g, 4.73 mmol) was dissolved in anhydrous tetrahydrofuran (5 mL), followed by the addition of a tetrahydrofuran solution of methylmagnesium bromide (1.13 g, 1 M, 9.45 mmol). After the addition, the mixture was warmed to room temperature and reacted at room temperature for 4 hours. TLC (PE:EA (V / V) = 3:1) showed that the reaction was complete. Saturated aqueous ammonium chloride solution (15 mL) was added to the reaction solution, extracted with ethyl acetate (20 mL×3), the organic phases were combined, washed once with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure and spin-dried, and the crude product was separated by normal phase silica gel column chromatography (PE / EtOAc (V / V) = 1:0-1:1) to give 1-(1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)ethan-1-one (1.10 g, yield: 92.66%).
[0212] Step 4: Synthesis of 1-(1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)ethan-1-ol
[0213]
[0214] Under ice bath conditions, 1-(1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)ethan-1-one (1.10 g, 4.38 mmol) was weighed and dissolved in methanol (10 mL), and then sodium borohydride (331.28 mg, 8.76 mmol) was added in batches. After the addition, the reaction solution was reacted at room temperature for 2 hours. TLC (PE:EA (V / V) = 3:1) showed that the reaction was complete. Saturated ammonium chloride solution (20 mL) was added to the reaction solution, extracted with ethyl acetate (20 mL×3), the organic phase was washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure and spin-dried, and the crude product was separated by normal phase silica gel column chromatography (PE / EtOAc (V / V) = 1:0-1:1) to give 1-(1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)ethan-1-ol (1.0 g, yield: 90.19%).
[0215] Step 5: Synthesis of 3-chloro-6-(1-(1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)ethoxy)pyridazine
[0216]
[0217] Under ice bath conditions and nitrogen protection, 1-(1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)ethan-1-ol (1.00 g, 4.38 mmol) was weighed and dissolved in tetrahydrofuran (10 mL), and then sodium hydride (236.90 mg, 60%, 5.92 mmol) was added in batches. After the addition, the reaction solution was reacted in an ice bath for 30 minutes, and then 3,6-dichloropyridazine (882.36 mg, 5.92 mmol) was added and reacted at room temperature for 10 hours. TLC (PE:EA (V / V) = 1:1) showed that the reaction was complete. Saturated ammonium chloride solution (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (20 mL×3). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure and spin-dried. The crude product was separated by normal phase silica gel column chromatography (PE / EtOAc (V / V) = 1:0-1:1) to give 3-chloro-6-(1-(1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)ethoxy)pyridazine (1.33 g, yield: 92.09%).
[0218] Step 6: Synthesis of 4-(6-(1-(1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)ethoxy)pyridazin-3-yl)piperazin-2-one
[0219]
[0220] Under argon protection, 3-chloro-6-(1-(1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)ethoxy)pyridazine (1.33 g, 3.64 mmol) and 2-piperazinone (364.06 mg, 3.64 mmol) were dissolved in dioxane (15 mL), and 2-bicyclohexylphosphino-2',6'-diisopropoxybiphenyl (16 9.68mg, 0.364mmol), cesium carbonate (1.18g, 3.64mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl) palladium (II) (304.12mg, 0.364mmol) were added. After the addition, the reaction solution was heated to 100°C and stirred for 16 hours under this condition. The reaction was completed by LCMS monitoring. The reaction solution was diluted with dichloromethane (50mL), filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase HPLC (column: SunFileTM Prep C18 OBDTM 5μm 30mm×150mm); solvent: A=acetonitrile, B=water; gradient: 1%-25%, 8 minutes) to give 4-(6-(1-(1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)ethoxy)pyridazin-3-yl)piperazin-2-one (600.0 mg, yield: 38.42%).
[0221] 1 H NMR (400 MHz, DMSO - d 6 ): δ8.14-8.10(m,1H),7.82(dd,4H,J 1 =8.0Hz,J 2 =20.0Hz),7.38(d,1H,J=12.0Hz),7.18-7.04(m,2H),6.15-6.10(m,1H),3.95(s ,2H),3.66-3.63(m,2H),3.28-3.25(m,2H),2.36(s,3H),1.60(d,3H,J=8.0Hz).
[0222] LC-MS, M / Z(ESI):430.1[M+H] +
[0223] Example 2: Preparation of target compound I-7
[0224] 1-(3-((6-((1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)pyridazin-3-yl)oxy)azetidin-1-yl)ethan-1-one
[0225]
[0226] The synthetic route of the target compound I-7 is as follows:
[0227]
[0228] Step 1: Synthesis of (1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methanol
[0229]
[0230] At 0°C, 2.5M lithium aluminum tetrahydride solution (5.2 mL) was added dropwise to a solution of 1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazole-5-carboxylic acid ethyl ester (2.60 g, 9.24 mmol) in tetrahydrofuran (30 mL), and the reaction solution was stirred at 0°C for 0.5 hours. After the reaction was completed, water (0.5 mL), 15% sodium hydroxide solution (0.5 mL) and water (1.5 mL) were added dropwise under a nitrogen atmosphere. The quenched mixed solution was dried over anhydrous sodium sulfate, filtered and concentrated to obtain (1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methanol (2.06 g, 8.61 mmol).
[0231] LC-MS, M / Z(ESI):240.0[M+H] +
[0232] Step 2: Synthesis of 3-chloro-6-((1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)pyridazine
[0233]
[0234] At 0°C and under nitrogen protection, sodium hydrogen (84.0 mg, 2.10 mmol, 60%) was slowly added to a solution of (1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methanol (250 mg, 1.05 mmol) and 3,6-dichloropyridazine (156 mg, 1.05 mmol) in tetrahydrofuran (3 mL), and the reaction solution was stirred at 25°C for 2 hours. After the reaction, the reaction solution was quenched with saturated ammonium chloride (20 mL) aqueous solution, extracted three times with ethyl acetate (20 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to obtain 3-chloro-6-((1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)pyridazine (350 mg, crude product).
[0235] LC-MS, M / Z(ESI):351.9[M+H] +
[0236] Step 3: Synthesis of 1-(3-((6-((1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)pyridazin-3-yl)oxy)azetidin-1-yl)ethan-1-one
[0237]
[0238] At 0°C and under nitrogen protection, sodium hydrogen (119 mg, 2.98 mmol, 60%) was added to a solution of 1-(3-hydroxyazetidin-1-yl)ethane-1-one (115 mg, 995 μmol) in tetrahydrofuran (4 mL) and N-methylpyrrolidone (2 mL), and then 3-chloro-6-((1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)pyridazine (350 mg, 995 μmol) was added to the reaction mixture. The reaction solution was stirred at 80°C for 1 hour under a nitrogen atmosphere. After the reaction was completed, the reaction solution was quenched with water (20 mL), extracted three times with ethyl acetate (20 mL), and the organic phase was dried over anhydrous sodium sulfate and filtered and concentrated to obtain a crude product. The crude product was purified by HPLC (chromatographic column: Phenomenex luna C18 150*25mm*10μm; mobile phase: solvent A=water+0.1% formic acid, B=acetonitrile; gradient: 25%-55%, 10min) to give 1-(3-((6-((1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)pyridazin-3-yl)oxy)azetidin-1-yl)ethan-1-one (80.0mg, 182μmol).
[0239] LC-MS, M / Z(ESI):431.1[M+H] +
[0240] 1 H NMR (400 MHz, CDCl 3 )δ7.71-7.66(m,4H),7.06(d,J=9.2,1H),7.00(d,J=9.2,1H),6.73(t,J=56Hz,1H),5.44-5.4 9(m,3H),4.49-4.47(m,1H),4.44-4.42(m,1H),4.19-4.11(m,2H),2.51(s,3H),1.92(s,3H).
[0241] Example 3: Preparation of target compound I-9
[0242] 1-(4-(Difluoromethyl)phenyl)-4-methyl-N-(6-(4-methyl-3-oxopiperazin-1-yl)pyridazin-3-yl)-1H-1,2,3-triazole-5-carboxamide
[0243]
[0244] The synthetic route of the target compound I-9 is as follows:
[0245]
[0246] Step 1: Synthesis of 4-(6-aminopyridazin-3-yl)-1-methylpiperazin-2-one
[0247]
[0248] At 25°C, 6-chloropyridazine-3-amine (200 mg, 1.54 mmol) and 1-methylpiperazine-2-one (212 mg, 1.85 mmol) were mixed together and then stirred at 150°C for 2 hours. After the reaction, the reaction solution was cooled to room temperature, and then methyl tert-butyl ether (5 mL) was added and stirred for 0.5 hours, and 4-(6-aminopyridazine-3-yl)-1-methylpiperazine-2-one (200 mg, crude product) was obtained by filtration.
[0249] LC-MS, M / Z(ESI):208.0[M+H] +
[0250] Step 2: Synthesis of 1-(4-(difluoromethyl)phenyl)-4-methyl-N-(6-(4-methyl-3-oxopiperazin-1-yl)pyridazin-3-yl)-1H-1,2,3-triazole-5-carboxamide
[0251]
[0252] At room temperature, a drop of N,N-dimethylformamide and oxalyl chloride (128 mg, 1.01 mmol) were added to a solution of 1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazole-5-carboxylic acid (170 mg, 672 μmol) in dichloromethane (3.00 mL), and the reaction solution was stirred at 25°C for 0.5 hours. After the reaction was completed, it was directly concentrated to obtain a crude product, which was dispersed with dichloromethane (2 mL), and then the dispersion was slowly added dropwise to a solution of 4-(6-aminopyridazin-3-yl)-1-methylpiperazin-2-one (146 mg, 705 μmol) and N,N-diisopropylethylamine (260 mg, 2.01 mmol) in dichloromethane (3 mL) at zero degrees, and the reaction solution was continued to be stirred at 25°C for 0.5 hours. After the reaction was completed, it was directly concentrated to obtain a crude product. The crude product was purified by HPLC (chromatographic column: Phenomenex luna C18 150*25mm*10μm; mobile phase: solvent A=water+0.1% formic acid, B=acetonitrile; gradient: 25%-45%, 10min) to give 1-(4-(difluoromethyl)phenyl)-4-methyl-N-(6-(4-methyl-3-oxopiperazin-1-yl)pyridazin-3-yl)-1H-1,2,3-triazole-5-carboxamide (81.7mg, 177μmol).
[0253] LC-MS, M / Z(ESI):443.2[M+H] +
[0254] 1 H NMR (400 MHz, CDCl 3 )δ10.3(s,1H),8.31(d,J=8Hz,1H),7.67-7.62(m,4H),6.94(d,J=9.6Hz,H),6.72(t,J=56.4 Hz,1H),4.03(s,2H),3.77(t,J=5.6Hz,2H),3.43(t,J=5.6Hz,1H),3.03(s,3H),2.57(s,3).
[0255] Example 4: Preparation of target compound I-14
[0256] 2-((1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxamide
[0257]
[0258] The synthetic route of the target compound I-14 is as follows:
[0259]
[0260] Step 1: Synthesis of tert-butyl 2-((1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate
[0261]
[0262] At 25°C, (1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methanol (300 mg, 1.25 mmol) and tert-butyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (371 mg, 1.37 mmol) were dissolved in tetrahydrofuran (6 mL), and potassium tert-butoxide (281 mg, 2.51 mmol) was added in batches, and the reaction system was stirred at 60°C for 12 hours. After the reaction was completed, the reaction solution was cooled to room temperature and diluted with water (10 mL). The mixed solution was extracted three times with ethyl acetate (30 mL). The combined organic phase was washed with saturated sodium chloride solution (20 mL) and dried over anhydrous sodium sulfate, then filtered and concentrated to give tert-butyl 2-((1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (520 mg, crude product).
[0263] LC-MS, M / Z(ESI):472.2[M+H] +
[0264] Step 2: Synthesis of 2-((1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)-5,6,7,8-tetrahydro-1,6-naphthyridine
[0265]
[0266] At 25°C, tert-butyl 2-((1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (500 mg, 1.06 mmol) was dissolved in dichloromethane (5 mL), trifluoroacetic acid (5 mL) was added, and the reaction solution was stirred at 25°C for 0.5 hours. After the reaction, the reaction solution was concentrated to obtain a crude product, which was separated and purified by reverse phase high performance liquid chromatography (chromatographic column: Phenomenex luna C18 150*25mm*10μm; mobile phase: solvent A=water+0.1% formic acid, B=acetonitrile; gradient: 12%-42%, 9min) to obtain 2-((1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)-5,6,7,8-tetrahydro-1,6-naphthyridine (250 mg, 63.5% yield).
[0267] LC-MS, M / Z(ESI):372.2[M+H] +
[0268] Step 3: Synthesis of 2-((1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxamide
[0269]
[0270] At 25°C, 2-((1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)-5,6,7,8-tetrahydro-1,6-naphthyridine (200 mg, 538 μmol) was dissolved in dichloromethane (4 mL), and triethylamine (218 mg, 2.15 mmol) and trimethylsilyl isocyanate (186 mg, 1.63 mmol) were added, and the reaction solution was stirred at 25°C for 1 hour. After the reaction, the reaction solution was poured into water (10 mL) for dilution, and then dichloromethane (5 mL) was added for extraction three times. The organic phases were combined, washed with saturated sodium chloride solution (10 mL) and dried over anhydrous sodium sulfate, and then filtered to obtain a crude product. The crude product was separated and purified by reverse phase high performance liquid chromatography (chromatographic column: Phenomenex luna C18 150*25mm*10μm; mobile phase: solvent A=water+0.1% formic acid, B=acetonitrile; gradient: 30%-60%, 9min) to obtain 2-((1-(4-(difluoromethyl)phenyl)-4-methyl-1H-1,2,3-triazol-5-yl)methoxy)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxamide (151 mg, 67.0% yield).
[0271] LC-MS, M / Z(ESI):415.1[M+H] +
[0272] 1 H NMR (400 MHz, CDCl 3 )δ7.75(d,J=8.4Hz,2H),7.67(d,J=8.4Hz,2H),7.34(d,J=8.4Hz,1H),6.72(t,J=56.4Hz,1H),6.60(d,J=8.4Hz,1H),5.36(s,2H),4.68(br s,2H),4.52(s,2H),3.69(t,J=6Hz,2H),2.88(t,J=5.6Hz,2H),2.51(s,3H).
[0273] Example 5: The following compounds were prepared by referring to the preparation methods of the above compounds.
[0274]
[0275]
[0276]
[0277] Test Example 1: Inverse agonist activity of compounds on α5-GABAA receptors
[0278] This test uses a HEK-293 cell line that transiently expresses GABAA (α5β3γ2) receptors. The final concentration of the test compound was prepared on the same day and dissolved in the extracellular solution. The extracellular solution is: 140mM NaCl, 5mM CsCl, 2mM CaCl 2 ·2H 2 O, 1 mM MgCl 2 6H 2 O, 5mM HEPES, 10mM D-Glucose, NaOH to adjust pH = 7.4. Intracellular solution: 130mM CsCl, 0.1mM CaCl 2 ·2H 2 O, 2 mM MgCl 2 6H 2 O, 1.1 mM EGTA, 5 mM Na2-ATP, 10 mM HEPES, CsOH to adjust pH = 7.2. The test compound was dissolved in dimethyl sulfoxide (DMSO) and redissolved in the extracellular fluid on the day of the test to a final concentration of 100 nM.
[0279] First, use a microelectrode puller to pull a capillary glass tube into a recording electrode, then load the electrode filled with intracellular fluid into the microelectrode holder, manipulate the microelectrode manipulator under an inverted microscope to immerse the electrode in the extracellular fluid and record the electrode resistance (Rpip). Then slowly contact the electrode to the cell surface, apply negative pressure to form a GΩ high-resistance seal. At this time, fast capacitance compensation is performed, and negative pressure is continued to be applied to break the cell membrane to form a whole-cell recording mode. Finally, slow capacitance compensation is performed and experimental parameters such as series resistance (Rs) are recorded. No leakage compensation is given. After the whole-cell seal is formed, the cell membrane voltage is clamped at -70mV and the GABA receptor current is recorded in the gap-free mode.
[0280] When detecting the reverse agonist effect of the test substance, the peak current after the EC50 concentration of GABA, the mixture of EC50 concentration of GABA and the test concentration of the test substance, and the saturated concentration of GABA are rapidly injected onto the cell surface in sequence. After each switching of the working solution, the cells are eluted with extracellular solution, and the next working solution is switched after the current stabilizes. The experimental data are collected by a patch clamp amplifier (HEKA, EPC10) and stored in the data acquisition software (HEKA, Patch Master). At least 2 cells are used for each concentration and the test is repeated 2 times independently. All electrophysiological experiments are carried out at room temperature. During the experiment, the peak current (I GABA ), the peak current after the test substance concentration is affected (I Cmpd ), the peak current after the mixture of the test substance detection concentration and GABA acts (I GABA+Cmpd ) and the peak current evoked by saturating concentration of GABA (I GABA saturated ) The antagonistic effect of the test substance was calculated during the analysis, i.e. (1-(I Cmpd / I GABA )*100%), reverse agonism, i.e. (1-(I GABA+Cmpd ) / (I GABA )*100%).
[0281] Table 1. Inverse agonist activity data of compounds (100 nM) at α5-GABAA receptor
[0282] Compound Inverse excitation rate I-1 45%
[0283] The experimental results show that the compound of the present invention has strong inverse agonist activity of α5-GABAA receptor.
[0284] The above is an exemplary description of the implementation of the technical solution of the present disclosure. It should be understood that the protection scope of the present disclosure is not limited to the above-mentioned implementation. Any modification, equivalent substitution, improvement, etc. made by those skilled in the art within the spirit and principle of the present disclosure shall be included in the protection scope of the claims of this application.
Claims
1. A compound as shown in formula I, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug: in, X1 is N or C; X2 is N, O, S or CR5; Dashed lines represent single or double bonds; m is selected from 0, 1, 2, 3, 4 or 5; Ring A does not exist or is selected from a benzene ring and a 5-6-membered heteroaromatic ring; wherein, when Ring A does not exist, m is 1, and R1 is connected to X1; R1 is selected from hydrogen, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 3-7 Cycloalkyl or 3-6 membered heterocycloalkyl; 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 3-7 The cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted by 1-4 substituents selected from the group consisting of deuterium, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; R2 is selected from hydrogen, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, 3-7 membered heterocycloalkyl or 5-6 membered heteroaryl; the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, 3-7 membered heterocycloalkyl or 5-6 membered heteroaryl are optionally substituted with 1-4 substituents selected from the group consisting of deuterium, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; L is selected from -CH2-O-, -CH(R6)-O- or -C(=O)-NR a -; Ring B is selected from 5-14 membered heteroaromatic rings; n is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8; Ring D is absent or selected from 4-6 membered heterocycloalkyl, 3-6 membered cycloalkyl; p is 0, 1, 2, 3, 4, 5, 6 or 7; R3 and R4 are each independently selected from hydrogen, halogen, hydroxy, amino, cyano, oxo, -C 0-6 Alkyl-C(=O)R a -C 0-6 Alkyl, -C 0-6 Alkyl-C(=O)OR a -C 0-6 Alkyl, -C 0-6 Alkyl-C(=O)NR a R b -C 0-6 Alkyl, -C 0-6 Alkyl-NR a R b -C 0-6 Alkyl, -C 0-6 Alkyl-NR a C(=O)R b -C 0-6 Alkyl, -C 0-6 Alkyl-NR a S02R b -C 0-6 Alkyl, -C 0-6 Alkyl-SO2R a -C 0-6 Alkyl, -C 0-6 Alkyl-SO2NR a R b -C 0-6 Alkyl, C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl, 6-10 membered heteroaryl; the C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl, 6-10 membered heteroaryl are optionally substituted by 1-4 substituents selected from the following groups: deuterium, halogen, oxo, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; M is absent or selected from O; R5 is selected from hydrogen, deuterium, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl; said C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 The cycloalkyl group is optionally substituted by 1 to 4 substituents selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; R6 is selected from deuterium, halogen, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl; said C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 The cycloalkyl group is optionally substituted by 1 to 4 substituents selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; R a and R b are each independently selected from hydrogen, deuterium, halogen, hydroxyl, amino, -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 and the 3-6 membered heterocycloalkyl group is a monocyclic ring containing 0, 1, 2 or 3 N atoms and 0, 1 or 2 atoms selected from O and S atoms.
2. The compound of formula (I) as claimed in claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: Said Selected from Preferably, the Selected from 3. The compound of formula (I) as claimed in claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The ring A does not exist or is selected from a benzene ring or a 6-membered heteroaromatic ring; the 6-membered heteroaromatic ring contains 1, 2, or 3 heteroatoms; m is 0, 1, 2, 3, 4 or 5; R1 is selected from hydrogen, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-7 Cycloalkyl, C 3-7 Halogenated cycloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy; Preferably, the heteroatom is selected from N, O, and S; when there are multiple heteroatoms, the heteroatoms are the same or different; Preferably, ring A is absent or is selected from a benzene ring, pyridine, pyrimidine, pyridazine, pyrazine or triazine; Preferably, the ring A is selected from * terminal is connected to X1; Preferably, Selected from For example When ring A is absent, m is 1, and R1 is connected to X1; More preferably, ring A is absent or selected from a benzene ring or pyridine.
4. The compound of formula (I) as claimed in claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The compound is selected from the following structures: wherein, ring B, ring D, R1, R2, R3, R4, L, M, m, n and p have the meanings as defined in claim 1.
5. The compound of formula (I) as claimed in claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The compound is selected from the following structures: wherein, ring A, ring B, ring D, R1, R2, R3, R4, M, m, n and p have the meanings as defined in claim 1.
6. The compound of formula (I) according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The compound is selected from the following structures: wherein Ring B, R1, R2, R3, m and n have the meanings as defined in claim 1; When M is absent, ring D, R4, and p are absent at the same time; When M is selected from O, ring D, R4 and p have the meanings as defined in claim 1.
7. The compound of formula (I) as claimed in claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The ring B is selected from a 5-14 membered heteroaromatic ring containing 1, 2, 3, 4 or 5 heteroatoms; Preferably, the heteroatom is selected from N, O, and S; when there are multiple heteroatoms, the heteroatoms are the same or different; Preferably, ring B is selected from acridinyl, carbazolyl, cinnolinyl, quinoxalinyl, quinazolinyl, pyrazolyl, indolyl, isoindolyl, 1H,3H-1-oxoisoindolyl, benzotriazolyl, furanyl, thienyl, pyridomorpholinyl, pyridopiperidinyl, pyridopyrrolidyl, benzothienyl, benzofuranyl, benzodioxane, benzodioxabenzophenone, quinolinyl, isoquinolinyl, oxazolyl, isoxazolyl, benzoxazolyl, tetrahydronaphthyridine , imidazolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrahydroquinolinyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, triazinyl, tetrazinyl, tetrazolyl, xanthenyl, phenazinyl, phenothiazinyl, phenoxazinyl, aza-zepinyl, oxa-zepinyl, thia-zepinyl, hexahydropyrazinopyrido-oxazine, 6,7,8,9-tetrahydropyrido[2',3':4,5]imidazo[1,2-a]pyrazine, and the like; More preferably, ring B is selected from pyridine, pyrimidine, pyridazine, tetrahydronaphthyridine, pyridopiperidine, Preferably, the ring B is selected from * end is connected to L; Preferably, Selected from * terminal is connected to L.
8. The compound of formula (I) as claimed in claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The L is selected from -CH2-O-, -CH(R6)-O- or -C(=O)-NR a -; The R6 is selected from C 1-3 Alkyl or C 3-5 Cycloalkyl; said C 1-3 Alkyl or C 3-5 The cycloalkyl group is optionally substituted by 1 to 4 substituents selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; Preferably, L is selected from -CH2-O-, -CH(R6)-O- or -C(=O)-NR a -; The R6 is selected from C 1-3 Alkyl or C 3-5 Cycloalkyl; said C 1-3 Alkyl or C 3-5 The cycloalkyl group is optionally substituted by 1 to 4 substituents selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; Preferably, L is selected from -CH2-O-, -CH(CH3)-O- or -C(=O)-NH-; Preferably, said L is selected from (like ), *End and connect.
9. The compound of formula (I) as claimed in claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The ring D is absent or selected from 4-6 membered heterocycloalkyl and 3-6 membered cycloalkyl containing 1-3 heteroatoms; Preferably, the heteroatom is selected from N, O, and S; when there are multiple heteroatoms, the heteroatoms are the same or different; Preferably, the ring D is absent or selected from cyclopropyl, cyclobutyl, cyclopentyl, azetidine, pyrrolidine, piperidine, piperazine; Preferably, the ring D is selected from Preferably, Selected from 10. The compound of formula (I) according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The R1 is selected from hydrogen, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl, C 1-6 Alkoxy; the C 1-6 Alkyl, C 3-7 Cycloalkyl, C 1-6 The alkoxy group is optionally substituted with 1 to 4 substituents selected from the group consisting of deuterium, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; m is selected from 0, 1, 2, 3, 4 or 5; Preferably, said R1 is selected from halogen, C 1-6 Alkyl, C 3-7 Cycloalkyl, C 1-6 Alkoxy, haloalkyl; Preferably, R1 is selected from F, methyl, cyclopropyl, methoxy, trifluoromethyl, difluoromethyl, monofluoromethyl.
11. The compound of formula (I) according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: R2 is selected from halogen, C 1-6 Alkyl, C 3-7 Cycloalkyl, C 1-6 Alkoxy; the C 1-6 Alkyl, C 3-7 Cycloalkyl, C 1-6 The alkoxy group is optionally substituted with 1 to 4 substituents selected from the group consisting of deuterium, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; Preferably, R2 is selected from methyl.
12. The compound of formula (I) as claimed in claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The R3 is selected from hydrogen, halogen, hydroxyl, amino, cyano, oxo, -C 0-6 Alkyl-C(=O)R a -C 0-6 Alkyl, -C 0-6 Alkyl-C(=O)OR a -C 0-6 Alkyl, -C 0-6 Alkyl-C(=O)NR a R b -C 0-6 Alkyl, C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl; the C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl are optionally substituted by 1-4 substituents selected from the following groups: deuterium, halogen, oxo, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; n is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8; Preferably, R3 is selected from hydrogen, halogen, oxo, -C(=O)R a 、-C(=O)NR a R b , C 1-3 Alkyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidine, piperidine, piperazine, piperidone, piperazinone; More preferably, R3 is selected from hydrogen, oxo, -C(=O)-CH3, -C(=O)NH2, -C(=O)NH-C 1-3 Alkyl, methyl, piperazinone, methyl substituted piperazinone; Preferably, R3 is selected from hydrogen, oxo, -C(=O)-CH3, -C(=O)NH2, methyl, n is selected from 0 or 1.
13. The compound of formula (I) according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The R4 is selected from hydrogen, halogen, hydroxyl, amino, cyano, oxo, -C 0-6 Alkyl-C(=O)R a -C 0-6 Alkyl, -C 0-6 Alkyl-C(=O)OR a -C 0-6 Alkyl, -C 0-6 Alkyl-C(=O)NR a R b -C 0-6 Alkyl, C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl; the C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-6 membered heterocycloalkyl are optionally substituted by 1-4 substituents selected from the following groups: deuterium, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; p is 0, 1, 2, 3, 4, 5, 6 or 7; Preferably, R4 is selected from hydrogen, oxo, -C(=O)-CH3, -C(=O)NH2, -C(=O)NH-C 1-3 Alkyl, methyl; p is selected from 0, 1 or 2.
14. The compound of formula (I) according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The compounds include:
15. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises: a compound of formula I as described in claims 1-14, a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof; and a pharmaceutically acceptable carrier.
16. Use of the compound of formula I as described in claims 1-14, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, or use of the pharmaceutical composition according to claim 15, comprising: Regulation of α5-GABA A Receptors; and / or, prevention and / or treatment of α5-GABA A Receptor-related diseases; And / or, preparing a method for regulating α5-GABA A Receptor, and / or prevention and / or treatment of α5-GABA A Drugs, pharmaceutical compositions or preparations for receptor-related diseases; Preferably, the α5-GABA A Diseases associated with the receptor include: pain, Alzheimer's disease, multi-infarct dementia, or stroke; Preferably, the pain is neuropathic pain, inflammatory pain or cancer pain; Preferably, the pain is selected from headache, facial pain, neck pain, shoulder pain, back pain, chest pain, abdominal pain, low back pain, lower limb pain, muscle and bone pain, vascular pain, gout, arthritis pain, visceral pain, pain caused by infectious diseases, polyostotic pain, sickle cell anemia, autoimmune disease, pain associated with multiple sclerosis or inflammation, chronic pain caused by injury or surgery, nociceptive pain, painful diabetes, trigeminal neuralgia, lumbar or cervical radiculopathy, glossopharyngeal neuralgia, autonomic reflex pain, reflex sympathetic dystrophy, nerve root avulsion, cancer, chemical injury, toxins, nutritional deficiencies, viral or bacterial infections, and pain associated with degenerative osteoarthritis; Preferably, the infectious disease is selected from AIDS or postherpetic neuralgia.
